The major protein of mature blood-stage schizonts of malaria parasites is sequentially processed during merozoite release and erythrocyte (RBC) reentry into a series of fragments collectively referred to as major merozoite surface protein 1 (MSP1) (15) . Of particular interest among these fragments are the cysteine-rich 19-kDa C terminus which contains two epidermal growth factor (EGF)-like domains (MSP1 19 ) and a C-terminal 42 kDa fragment (MSP1 42 ) which includes MSP1 19 (4) . A large body of evidence suggests that MSP1 is a target of protective immunity against asexual blood-stage malaria parasites. Several monoclonal antibodies (MAbs) that recognize the cysteine-rich EGF-like domains on MSP1 19 (2, 3) and polyclonal antibodies raised against MSP1 42 (8) inhibit the invasion of erythrocytes by Plasmodium falciparum merozoites. However, the most direct evidence establishing MSP1 as a vaccine candidate comes from in vivo challenge studies conducted in murine and monkey models. More than a decade ago it was demonstrated that immunization with native MSP1 confers protection against lethal P. yoelii in mice (16) and against P. falciparum in monkeys (22) . Also, MAb 302, which recognizes an epitope in the first EGF-like domain of P. yoelii MSP1 19 , protects mice against lethal parasite challenge (7). In more recent years, several laboratories have demonstrated that immunization with recombinant MSP1 42 (rMSP1 42 ) or rMSP1 19 protects mice against P. yoelii (10, 20, 23, 24) and monkeys against P. falciparum (9, 19) .
We have previously reported the expression of MSP1 19 as a His 6 -tagged fusion protein with two universal helper T-cell epitopes of tetanus toxoid, P30P2 (yP30P2MSP1 19 ). This fusion protein is secreted from Saccharomyces cerevisiae and elicits protection in Aotus nancymai from an otherwise lethal challenge infection (19) . The protective formulation included complete Freund's adjuvant (CFA). These findings warranted new studies to further evaluate and develop yP30P2MSP1 19 as a vaccine candidate and to search for a delivery system that is appropriate as a constituent of vaccine for human use. Here we report additional studies with yP30P2MSP1 19 in various adjuvant formulations as well as in comparison with three additional rMSP1 19 constructs in Aotus monkeys.
ultrafiltrate by sequential nickel agarose and size exclusion chromatography followed by concentration and aseptic filtration and stored at Ϫ75°C.
(iv) yEVE-MSP1 19 . The construct consists of amino acids E, V, and E on the NH 2 terminus of the MSP1 19 sequence with a terminal His 6 tag. To create yEVE-MSP1 19 , the gene fragment for MSP1 19 was PCR amplified from the genomic DNA of the FVO strain of the parasite, using sense (5Ј-CTGGTACC TTTGGATAAAAGAGAAGTAGAAAACATTTCACAACACCAATGT-3Ј) and antisense 5Ј-CCACTAGTGGTGGTGGTGGTGACTGCAGAAAATACC ATC-3Ј) primers. The PCR-amplified gene fragment was ligated to pIXY 154 into KpnI-SpeI restriction sites, and the recombinant plasmid was electroporated into S. cerevisiae 2905/6 cells. The recombinant protein was expressed in a clean room, using the procedure described above.
(v) yMSP1 19 . A nonfused version of MSP1 19 of the FVO strain of P. falciparum was expressed as a His 6 -tagged protein in S. cerevisiae (yMSP1 19 ). The procedures for plasmid construction, expression, and protein purification were described earlier (18) . This protein was used as a capture antigen in enzymelinked immunosorbent assay (ELISA).
(vi) bGST-MSP1 19 . The protein was expressed in E. coli as a fusion between Schistosoma japonicum glutathione S-transferase (GST) and MSP1 19 of the FVO strain of P. falciparum (bGST-MSP1 19 ). The procedures for the plasmid construction, protein expression, and purification have been described earlier (5) .
Adjuvants. The following adjuvants were used in this study: CFA and Freund's incomplete adjuvant (IFA), Rehydragel alum (Reheis, Inc.), SBAS2 (SmithKline Beecham Pharmaceuticals, Inc., Rixensart, Belgium), Montanide ISA 720 (Seppic, Inc.), lipid A in liposomes (lipid A/liposomes), polyphosphazine (Avant Immunotherapeutics, Inc., Needham, Mass.) and microspheres (Immunex).
Immunization. During the course of this study, three vaccine trials were conducted at two different locations. Two of these trials were carried out at the animal facility of the National Institutes of Health (NIH; Bethesda, Md.) (NIH trials 1 and 2), and the third trial was conducted at the Chamblee campus of the Centers for Disease Control and Prevention (CDC trial). The vaccination schedule and parasite challenge for NIH trial 2 was synchronized with the CDC trial with the goal of comparing the protective adjuvant effect of CFA with six other adjuvants that are suitable for human use. Blood was drawn from each monkey on the day of each immunization and on the day of, and in most instances 4 weeks after, the parasite challenge. Serum samples were separated and stored frozen at Ϫ70°C until used.
NIH trial 1. The purpose of the first trial was to confirm the protective efficacy of yP30P2MSP1 19 and to test the vaccine efficacy of yEVE-MSP1 19 and bGST-MSP1 19 in CFA. All three vaccines contained the MSP1 19 sequences from the FVO parasite. The protective efficacy of yP30P2MSP1 19 (lot 940826) was tested in A. nancymai and A. vociferans. yEVE-MSP1 19 (lot 941107) and bGST-MSP1 19 (lot 941130) vaccines were tested in A. nancymai. Aotus monkeys of both sexes were used in this study. The monkeys were housed at the Primate Research Facility, NIH, according to the NIH guideline for the care and use of laboratory animals. Monkeys were stratified according to sex and then assigned to each group by card draw. The immunization and parasite challenge parts of the study were performed blinded to the investigators who were actively involved in the process. Aotus monkeys, two in each group, were immunized with 0.5 ml of an emulsion containing 250 g of the recombinant protein of interest comprised of equal volumes of the antigen in phosphate-buffered saline (PBS) and CFA. The same immunization regimen was repeated on days 21 and 42 in IFA.
NIH trial 2. The second trial was conducted to determine the efficacy of clinical-grade yP30P2MSP1 19 against homologous and heterologous P. falciparum challenge. A. nancymai monkeys, four in each group, were immunized with 250 g of yP30P2MSP1 19 containing FVO (lot 0195) and 3D7 (lot 0207) MSP1 sequences produced using GMPs. The recombinant proteins were emulsified in an equal volume of CFA as in NIH trial 1. Immunizations were repeated on days 21 and 42 with IFA. The control monkeys were immunized with a transmissionblocking vaccine candidate antigen, Pfs25, produced in yeast under GMP conditions and delivered in CFA followed by two injections in IFA.
In this trial, we also compared the adjuvant efficacy of Montanide ISA 720 with Freund's adjuvant delivered with the FVO version of yP30P2MSP1 19 . A. nancymai monkeys, four in each group, were immunized with 250 g of yP30P2MSP1 19 delivered in Montanide ISA 720 by an immunization regimen similar to that followed with Freund's adjuvant. Control monkeys, four in each group, received TBV25H in Freund's adjuvant or Montanide ISA 720. Blood was drawn from each monkey on the day of each immunization and on the day of, and in most instances 4 weeks after, the parasite challenge. Serum samples were separated and stored frozen at Ϫ70°C until used.
CDC trial. Six adjuvant formulations of yP30P2MSP1 19 vaccine were tested for the ability to induce protection in A. nancymai. All vaccines were formulated from the same lot of bulk antigen (lot 0195) produced by the DBR at WRAIR. Except as noted below, each group contained three animals, each of which received 0.8 ml of vaccine subcutaneously containing 200 g of antigen IM on days 0, 28, and 56.
Alum-adsorbed vaccine was formulated for a phase I human trial by the DBR using aluminum hydroxide (Rehydragel LV) to contain antigen (200 g/ml) and aluminum (800 g/ml); 88% of the protein was bound to alum. The vaccine is designated yP30P2MSP1 19 FVO (lot 0245, BPR no. BPR-139-00). Animals received 1 ml of vaccine in each injection. Due to variation in alum and antigen concentrations discovered among other vials of the same lot after the study was completed, animals may have received more or less than the calculated dose. However, no variation in opacity among the vials used for the study was noted.
SBAS2-adjuvanted vaccine was formulated at SmithKline Beecham Pharmaceuticals by Natalie Garcon to contain 250 g of antigen per ml of vaccine.
Montanide ISA 720-adjuvanted vaccine was formulated at the Laboratory of Parasitic Diseases, NIH, by David Kaslow to contain 250 g of antigen per ml of vaccine. It was emulsified by 10ϫ expulsion through a 21-gauge needle and stored under nitrogen.
Vaccine adjuvanted with lipid A (Salmonella enterica serovar Minnesota R595) in liposomes was formulated in the Department of Membrane Biochemistry at the WRAIR by Roberta Owens to contain 250 g of antigen per ml of vaccine.
Polyphosphazine-adjuvanted vaccine was formulated at the Avant Immunotherapeutics to contain 250 g of antigen per ml of vaccine.
Vaccine in microspheres with granulocyte-macrophage colony-stimulating factor was formulated at the Immunex by Dean Pettet and at the Laboratory of Parasitic Diseases, NIH, by David Kaslow, immediately before administration. Animals were given a single immunization subcutaneously.
Parasite challenge. The FVO strain of P. falciparum was used to challenge Aotus monkeys. In all three studies, the challenge inoculum was obtained by infection of naive monkeys inoculated with a frozen stock of FVO parasites. Aliquots of the same frozen stabilate were used for NIH trial 2 and the CDC trial. In all the trials, 2 weeks after the third immunization, monkeys were challenged by the intravenous route with 10 4 P. falciparum parasitized RBCs with the exception of the group of monkeys immunized with the yP30P2MSP1 19 microsphere formulation (CDC trial). In this group, monkeys were challenged 58 days after a single-dose immunization. Three days after the challenge infection, blood smears were taken daily and parasitemias were quantified following staining with Giemsa stain and counting with the help of light microscopy. Immunized Aotus monkeys that required treatment with mefloquine to control their parasitemia were considered as nonprotected. The criterion for treatment was if the parasitemia in the challenged monkeys exceeded 5% or the hematocrit dropped below 25%. Monkeys were treated with 50 mg of mefloquine at the NIH facility and at with 20 mg of mefloquine and 50 mg of quinine sulfate at the CDC facility.
Serologic assays. (i) ELISA. For ELISA, 96-well microtiter plates were coated with 0.1 g of yMSP1 19 per 0.1 ml in each well. The plates were incubated overnight at 4°C, washed three times with PBS-0.05% Tween 20, and then blocked with PBS-1% bovine serum albumin (BSA) for 1 h at 37°C. Dilutions of test sera were added to wells and incubated for 1 h at 37°C. Following washings, alkaline phosphatase conjugated anti-human immunoglobulin (IgG; Promega) was added to wells as secondary antibody and incubated for 1 h at 37°C. After washings, solubilized phosphatase tablets (Sigma Chemical Co., St. Louis, Mo.) were added as substrate. Following incubation at room temperature, the plates were read at an absorbance of 410 nm.
Indirect immunofluorescence (IIF). P. falciparum (FVO) parasites, obtained directly from infected Aotus monkeys or from in vitro cultures, were air dried on toxoplasmosis slides (Bellco Glass, Vineland, N.J.) and fixed with ice-cold methanol for 15 min before use. The slides were washed with PBS and then blocked with PBS-3% BSA for 1 h at room temperature. A 1:100 dilution of Aotus sera in PBS-1% BSA was preabsorbed with washed human RBCs for 1 h at room temperature. The preabsorbed sera were added to the wells and incubated overnight at 4°C in a humid chamber. After washing with PBS, fluorescein isothiocyanate-conjugated goat anti-human IgG (Cappel, West Chester, Pa.) at a 1:200 dilution in PBS was added to wells and incubated for 2 h at room temperature in the dark. After washings, slides were mounted with a coverslip using Fluoromont solution (Southern Biotechnology) and were read by using a fluorescent light microscope.
MSP1 secondary processing inhibition by Aotus sera. The effects of the Aotus sera on secondary processing of MSP1 on the surface of intact merozoites were analyzed using a modification of the assay described previously (3). Naturally released merozoites of the P. falciparum T9/96 clone were isolated (1) and washed twice in serum-free RPMI 1640 medium. Washed merozoites were resuspended in ice-cold 50 mM Tris-HCl (pH 7.5) containing 10 mM CaCl 2 and 2 mM MgCl 2 , supplemented with protease inhibitors antipain, leupeptin, and aprotinin at 10 g/ml and tosyl-L-lysyl choromethyl ketone (TLCK) at 74 g/ml (reaction buffer). Aliquots of approximately 10 9 merozoites were dispensed into 1.5-ml Eppendorf tubes on ice in 18 l of reaction buffer. Each aliquot was supplemented with 2 l of serum. Control samples were supplemented with reaction buffer only or with phenylmethylsulfonyl fluoride (1 mM, final concentration), which is a potent inhibitor of the processing activity. Samples were mixed, incubated on ice for 15 min, and then centrifuged at 12,000 ϫ g at 4°C for 10 min. Half of the supernatant was removed and then the merozoites were transferred to 37°C for 1 h for processing to proceed. Samples were then solubilized by the addition of 20 l of 2ϫ sodium dodecyl sulfate (SDS) sample buffer (nonreducing), heated, and clarified, and the extracts were analyzed by Western blotting using the anti-MSP-133 MAb X509 (4). Antibody binding was detected using horseradish peroxidase-conjugated goat anti-human IgG (Bio-Rad) and enhanced chemiluminescence (SuperSignal Western blotting substrate; Pierce). Sera were tested in two independent assays.
RESULTS
This study had two major objectives. First, we compared the protective efficacies of four different versions of rMSP1 19 vaccines. Second, we tested whether yP30P2MSP1 19 could induce protective immunity when delivered in adjuvant formulations suitable for use in humans.
Two of these recombinant proteins, yP30P2MSP1 19 and bGST-MSP1 19 , have been described before (5, 19) . The protective yP30P2MSP1 19 construct was expressed in S. cerevisiae as a histidine-tagged, secreted protein. The recombinant plasmid was designed to express MSP1 19 as a fusion with the P30 and P2 epitopes that contain 30 amino acid residues. However, the NH 2 -terminal sequencing of GMP-produced yP30P2MSP1 19 determined by automated Edman degradation (Biological Resource Branch, National Institute of Allergy and Infectious Diseases) revealed that the major product is truncated, with only three C-terminus residues of P2P30 sequences, EVE, remaining for lot 940826 and eight residues, FIGITEVE, for lot 0245. Thus, the resultant recombinant protein is heterogeneous, making it difficult to define the protective immunogen used for vaccination. As an approach to circumvent this problem, we fused three additional amino acids, EVE, at the NH 2 terminus of MSP1 19 , creating the construct yEVE-MSP1 19 expressed as a His 6 -tagged, secreted protein in S. cerevisiae. Analysis of yEVE-MSP1 19 by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and by Western blot analysis indicated the presence of a band of the predicted molecular weight (data not shown). Furthermore, automated Edman degradation amino acid sequencing of the NH 2 terminus of the purified protein revealed that EVE-MSP1 19 was expressed as a fulllength protein.
In this study, we also constructed and expressed the 3D7 version of yP30P2MSP1 19 as a His 6 -tagged fusion protein in S. cerevisiae in secreted form under GMPs (lot 0207). Analysis of yP30P2MSP1 19 3D7 by SDS-PAGE, Western blotting, and NH 2 -terminal sequencing reveal this protein to be truncated in the same manner as the FVO product, having FIGITEVE as its NH 2 terminus.
The immunogenicity and efficacy of rMSP1 19 vaccines were determined in three independent trials in the P. falciparum- Aotus challenge model. Two of these trials were conducted at the NIH, and the third was done at the CDC.
NIH trial 1. In this trial, vaccines representing the MSP1 19 sequence from the FVO strain of P. falciparum were compared in the P. falciparum-Aotus challenge model. Monkeys were stratified according to species and sex and randomly assigned to one of the following groups. Two controls, one A. nancymai and one A. vociferans, received CFA in the absence of any immunogen. Two A. nancymai and two A. vociferans monkeys received the yP30P2MSP1 19 FVO emulsified in CFA. In the other two groups, A. nancymai, two in each group, received yEVE-MSP1 19 or bGST-MSP1 19 vaccine emulsified in CFA. For the first immunization, the vaccines were emulsified in CFA; subsequent injections were given in IFA on days 21 and 42, and 2 weeks later animals were challenged with 10 4 parasitized RBCs of the FVO strain of P. falciparum. Following challenge infection, an infection control A. nancymai (2048), vaccinated with CFA alone, developed a peak parasitemia of 5.5% on day 16 postchallenge and received chemotherapy. Both of the A. nancymai monkeys vaccinated with yP30P2MSP1 19 (2096 and 1432) were able to resolve their infection after reaching a peak parasitemia of 0.2% ( Fig. 1 and Table 1 ). In comparison, immunization with yEVE-MSP1 19 did not protect against FVO challenge, and both A. nancymai monkeys (1442 and 2053) required chemotherapy. The two A. nancymai monkeys (1597A and 2052) immunized with bGST-MSP1 19 were also not protected and required treatment by day 16. The courses of their parasitemia were very similar to that for the control A. nancymai 2048 (Fig. 1) . Thus, in this trial, among the three rMSP1 19 Having established that immunization with yP30P2MSP1 19 in CFA is capable of inducing protective immunity in A. nancymai, we next wanted to (i) search for an alternative protective adjuvant formulation that is suitable for use in humans and (ii) to determine whether yP30P2MSP1 19 vaccine will protect against challenge with a heterologous strain of P. falciparum. To address these questions, we conducted two concurrent vaccine trials, one at the NIH (NIH trial 2) and the other at the CDC.
NIH trial 2. The purposes of NIH trial 2 were to (i) compare the adjuvant efficacy of Montanide ISA 720 with CFA and (ii) determine the effect of heterologous parasite challenge on yP30P2MSP1 19 vaccine efficacy. A. nancymai monkeys, four in each group, were given three immunizations with either the FVO or 3D7 version of yP30P2MSP1 19 e Self-clear, infection cleared after reaching a low-grade parasitemia; virulent, above 5% parasitemia requiring treatment. f Reaction against the FVO strain of P. falciparum. Sera were taken on day 14 after the third immunization (the day of parasite challenge). g Determined at A 410 of 0.5, using MSP1 19 QKNG as capture antigen. Pre, sera taken on the day of parasite challenge; Post, sera taken 4 weeks after the parasite challenge; ND, not determined.
CFA became parasitemic and required chemotherapy on or before day 22 (Fig. 2) . Three (2068, 2104, and 2095) of the four A. nancymai monkeys immunized with yP30P2MSP1 19 FVO in CFA were protected after reaching peaks parasitemia of 0.5, 0.1, and 1%, respectively. A. nancymai 2084 could not control its infection and received treatment on day 28 ( Fig. 2 and Table 2 ). In comparison, two of the four A. nancymai monkeys (2062, 2110, 2082, and 2119) immunized with yP30P2MSP1 19 3D7 were protected; A. nancymai 2110 and 2082 self-resolved their infection after reaching peak parasitemias of 0.1 and 0.2%, respectively (Fig. 2) . A. nancymai monkeys 2062 and 2119 received chemotherapy at low parasitemias of 0.5 and 1%, respectively ( Fig. 2 and Table 2 ), because of severe anemia (hematocrit below 25%), suggesting that rMSP1 19 vaccine induced partial protection against heterologous parasite challenge.
Immunization with yP30P2MSP1 19 in Montanide ISA 720 resulted in protection of only one of four A. nancymai monkeys. A. nancymai 2091 and 2123 developed parasitemias of 5 and 6%, respectively, and received chemotherapy. A. nancymai 2101 maintained low-grade parasitemia but failed to clear infection and had to be treated at 1.0% parasitemia on day 26 because its hematocrit dropped below 25%. A. nancymai 2118 was protected and had no detectable parasitemia for the 60-day observation period (Fig. 2 and Table 2 ). Among the four A. nancymai (2027, 2036, 2097 , and 2094) immunized with the TBV25H control vaccine in ISA 720, two (2036 and 2097) of four developed high parasitemia and received chemotherapy on or before day 27 (Fig. 2) . A. nancymai monkeys 2027 and 2094 self-cleared their infection after reaching peak parasitemias of 1 and 0.05%, respectively ( Fig. 2 and Table 2 ). These data suggest that Montanide ISA 720 has some nonspecific protective effect against erythrocyte-stage malaria and is less potent than Freund's adjuvant in its ability to induce MSP1 19 -specific protective immune responses.
There were no significant differences in the IgG titers of the sera from A. nancymai immunized with either the 3D7 or FVO version of yP30P2MSP1 19 in CFA. More significantly, the protected and nonprotected A. nancymai had similar IgG titers (Table 2) . However, immunization with yP30P2MSP1 19 in Montanide ISA 720 induced substantially lower antibody titers ( Table 2 ), suggesting that CFA is more potent in inducing anti-MSP1 19 antibody responses. No significant boosting in MSP1-specific ELISA IgG titers were seen in the Aotus sera immunized with either vaccine-adjuvant formulation following parasite challenge (Table 2) .
CDC trial. This trial was conducted in an attempt to find a potent adjuvant comparable to CFA in its ability to induce protective immunity when delivered with rMSP1 19 . With this aim, the following six adjuvants were tested: alum, SBAS2, Montanide ISA 720, lipid A/liposomes, polyphosphazine, and microspheres. A. nancymai monkeys were immunized with FIG. 2. Parasitemia curves for infections of the FVO strain of P. falciparum in A. nancymai monkeys immunized with the FVO or 3D7 version of yP30P2MSP1 19 or TBV25H in CFA (A to C) and yP30P2MSP1 19 or TBV25H in Montanide ISA 720 (D and E). SC, self-cleared infection; A, treated for severe anemia (hematocrit below 25%); P, treated for parasitemia above 5%. yP30P2MSP1 19 FVO formulated in each of these adjuvants. Control A. nancymai monkeys received normal saline injection. Each group included three A. nancymai monkeys with the exception of microsphere-vaccine formulation group, which had two. Upon FVO challenge, the three control A. nancymai monkeys (AI1112, AI1113, and AI2009) developed patent infections by day 7 and were treated on or before day 18. In the vaccinated groups, none of the A. nancymai monkeys immunized with yP30P2MSP1 19 delivered in either of the six adjuvant formulations were protected (Fig. 3) . The course of parasitemias in the immunized A. nancymai were essentially similar to that in the control A. nancymai and required chemotherapy on or before day 17 after the challenge infection (Fig. 3) . Thus, it appears that none of the six adjuvants tested were capable of inducing a MSP1 19 -specific protective immune response in the P. falciparum-Aotus challenge model.
Immunization with these yP30P2MSP1 19 -adjuvant formulations induced moderate to low levels of anti-MSP1 19 ELISA and IIF IgG responses (Table 3) . In general, these responses were significantly lower than for rMSP1 19 -CFA vaccine formulations (Tables 1 and 2 
versus 3).
Correlation between MSP1 processing inhibition and protection. To investigate the mechanism(s) of protective immunity, sera from protected and nonprotected Aotus were tested for the ability to inhibit the secondary processing of MSP1 42 on P. falciparum merozoites in a semiquantitative MSP1 processing inhibition assay (13) . Four levels of inhibition were observed: just detectable, significant, strong, and apparently complete. Sera from Aotus monkeys vaccinated with three different rMSP1 19 vaccines (yP30P2MSP1 19 3D7 and FVO; bGST-MSP1 19 FVO) delivered in Freund's adjuvant were tested in two independent assays. c Day monkeys received treatment with mefloquine to cure parasitemia. (A), treatment given for severe anemia (hematocrit below 25%); (P), treatment given for parasitemia above 25%.
d Self-clear, infection cleared after reaching a low-grade parasitemia; virulent, above 5% parasitemia requiring treatment. e Reaction against the FVO strain of P. falciparum. Sera were taken on day 14 after the third immunization (the day of parasite challenge). f Determined at A 410 of 0.5 using yMSP1 19 QKNG as capture antigen. Pre, sera taken on the day of parasite challenge; Post, sera taken 4 weeks after the parasite challenge; ND, not determined. a Following P. falciparum (FVO) challenge, all monkeys in this trial reached a parasitemia of more than 5% and required treatment.
b Reaction against the FVO strain of P. falciparum. Sera were taken on the day of parasite challenge.
c Determined at A 410 of 0.5 using yMSP1 19 QKNG as capture antigen. Pre, sera taken on the day of parasite challenge; Post, sera taken 4 weeks after the parasite challenge; ND, not determined. (Table 4) . No processing-inhibitory activity was detected in any sera from animals immunized with TBV25H. Processing inhibition directly correlated with ELISA and IIF titers in the sera of vaccinated Aotus monkeys. Sera that had anti-MSP1 19 ELISA titers of more than 16,000 (determined at an optical density of 0.5 at A 410 ) or endpoint IIF titer of 10 6 showed apparently complete or strong inhibition of MSP1 42 processing (Table 4) .
DISCUSSION
We have previously demonstrated that vaccination with the yeast-produced 19-kDa carboxyl terminus of MSP1 fused to two universal helper T-cell epitopes of tetanus toxoid emulsified in CFA protected A. nancymai against the virulent FVO strain of P. falciparum (19) . This raised the prospect of a MSP1-based vaccine that will protect humans against erythrocyte-stage malaria parasites. However, several issues remained to be resolved to guide vaccine formulation for human use. First, the major immunogen used for the vaccination was not full length but consisted of cleaved products that contained only three to eight amino acid residues from the tetanus toxoid sequences. Second, the protective formulation included CFA, which is not suitable for use in humans. Third, it is not clear whether a MSP1 19 -based vaccine that contains sequence representing a single MSP1 allele will protect humans in the field, where infection with parasites having one or more allelic forms of MSP1 is common.
In this study, we tested the immunogenicity and in vivo protective efficacy of four rMSP1 19 constructs in the P. falciparum-Aotus model. All rMSP1 19 vaccines when delivered in CFA were highly immunogenic and, with the exception of yEVE-MSP1 19 vaccine, induced comparable levels of antibody responses (Tables 1 and 2 ). In NIH trial 1, among the three rMSP1 19 vaccines, yP30P2MSP1 19 , yEVE-MSP1 19 , and bGST-MSP1 19 , only yP30P2MSP1 19 protected A. nancymai against FVO challenge ( Fig. 1 and 2) . Together, in two trials reported here, five of six A. nancymai monkeys self-resolved their infection without antimalarial chemotherapy. yEVE-MSP1 19 and bGST-MSP1 19 had no detectable protective effect. Furthermore, under similar vaccination conditions, yeast-produced nonfused MSP1 19 also failed to induce protective immunity in A. nancymai against FVO challenge (A. Egan and D. C. Kaslow, unpublished data). Previously, vaccination with bGST-MSP1 19 adjuvanted with liposomes and alum failed to protect A. nancymai against virulent FVO challenge (6). In this context, it is important to mention that in the P. yoelii murine model, both bGST-MSP1 19 (10, 24) and yeast-produced nonfused MSP1 19 (yPyMSP1 19 ) (14) It is not clear why yP30P2MSP1 19 truncated to EVE-MSP1 19 (19) but not nontruncated yEVE-MSP1 19 (this report) induces protection. It is possible that the minor fraction of purified full-length protein present in the immunogen contributed to immunity. Another, more likely possibility is that prior to cleavage, the P30P2 sequences influenced the conformation of rMSP1 19 . Three lines of evidence suggest a complex relationship between conformational folding of MSP1 19 and protective immunity. First, MAbs that inhibit parasite growth in vitro recognize epitopes that are reduction sensitive (2) . Second, alkylation abolishes the protective effect of P. yoelii bGST-MSP1 19 (20) . Third, reduced MSP1 gave better T-cell responses than nonreduced in parasite-exposed populations (12) .
Using the three-dose immunization regimen described, yP30P2MSP1 19 in Freund's adjuvant formulation failed to protect A. vociferans monkeys. This result is in agreement with our previous study in which three vaccinations with yP30P2MSP1 19 in Freund's adjuvant did not protect A. vociferans, suggesting that immunity is host species dependent (19) . However, A. Egan et al. recently found (12a) that a fourth intramuscular injection with immunogen in the absence of adjuvant protected A. vociferans. Whether or not an rMSP1 19 -based vaccine will induce protective immune responses in a HLA allele-diverse human populations remains to be seen.
The allelic diversity of MSP1 19 raises a question about the effectiveness of an MSP1 19 -based vaccine encoding only one allelic form. In this study, both the FVO and 3D7 versions of yP30P2MSP1 19 induced high levels of IIF and ELISA titers in A. nancymai (Table 2 ). Nonetheless, monkeys that received vaccine from 3D7 sequences appeared to have a slightly lower degree of protective immunity against FVO parasites (Fig. 2) . The effect that MSP1 sequence diversity will have on the outcome of an MSP1-based vaccine in the field is not known. It is plausible that it may be necessary to incorporate MSP1 sequences from multiple parasite clones that are prevalent in the area where the vaccine is administered.
In three separate trials (reference 19 and the present study), we have shown that immunization with yP30P2MSP1 19 (Tables 1 and 2 versus 3) . Among the six adjuvants tested, MSP1 19 -alum induced the lowest levels of antibody response (Table 3) . Although none of the non-Freund's adjuvant-vaccine formulations protected A. nancymai against FVO challenge, it remains to be seen whether these rMSP1-nonFreund's adjuvant formulations will be able to induce protective immune responses in humans, especially those previously exposed to malaria parasites.
The mechanism of MSP1-induced immunity in the P. falciparum-Aotus model is still unclear. In our previous study, prechallenge sera from MSP1 19 vaccinated Aotus monkeys that survived challenge with virulent FVO failed to block parasite growth in vitro, suggesting that neutralizing antibodies may not be the only mechanism of immunity (19) . Blackman and colleagues have demonstrated that protective anti-MSP1 19 MAbs that inhibit merozoite invasion also prevent the secondary processing of MSP1 on the surface of extracellular merozoites at or around the time of invasion (3). On the other hand, some MAbs that have no effect on parasite invasion (nonprotective) negate the effect of antibodies that inhibit MSP1 processing (3, 19 or control TBV25H vaccine was delivered in CFA. Sera used for these assays were taken on day 14 after the third immunization (the day of parasite challenge).
b Self-cleared infection. c N, A. nancymai; V, A. vociferans. Ϫ, no detectable processing inhibition; ϩ/Ϫ, just detectable processing inhibition; ϩ, significant processing inhibition; ϩϩ, strong processing inhibition; ϩϩϩ, apparently complete processing inhibition; ϩϩ(ϩ), d Endpoint IIF titer against the FVO strain of P. falciparum parasites. e Determined at A 410 of 0.5 using yMSP1 19 QKNG as capture antigen.
13). In the present study, the majority of the sera from the rMSP1 19 -vaccinated monkeys effectively inhibited the secondary processing of MSP1, but their inhibitory effect had no correlation with protective immunity (Table 4) . Sera from both protected and nonprotected Aotus monkeys had similar inhibitory effects, suggesting that the presence of these antibodies may not be sufficient to control parasitemia. Thus, the mechanism(s) of MSP1-induced immunity in the Aotus model remains largely unclear. In our studies (this report [NIH trials 1 and 2] and reference 19) , there were no obvious differences in the prepatency (the time of the first appearance of parasitemia) between the protected and nonprotected monkeys. This suggests that antibodies present at the time of challenge that block the merozoite invasion were not the primary mediator of immunity and other factors contributed to parasite clearance. In the P. yoelii-murine model, the mechanism of anti-MSP1 19 immunity has been shown to be antibody dependent. In these studies, prechallenge sera from vaccinated mice transfer protection into naive recipients (11, 24; Chun and Kaslow, unpublished data). The sera from immune mice had predominantly IgG1 subclass, a product of the Th2-type response (14, 24) . An rMSP1 19 vaccine that will successfully protect humans against P. falciparum malaria may require the use of a potent non-Freund's adjuvant-based formulation. Research is in progress in several laboratories to search for an alternative adjuvant(s) that would induce protective immune responses in humans when delivered with rMSP1 or other malaria vaccine candidate antigens.
